Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.64 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.55 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | ADH5 | P11766 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29232997 | 0.98 | LMNA (0.62) | LMNAMAPTENPP2MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL28349198 | 0.98 | LMNA (0.62) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL2532397 | 0.89 | LMNA (0.78) | LMNAMAPTENPP2MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL28701756 | 0.86 | LMNA (0.75) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL4912541 | 0.83 | KMT2A (0.61) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL2533488 | 0.82 | TSHR (0.84) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL3250899 | 0.79 | CYP3A4 (0.71) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL30912606 | 0.79 | LMNA (0.60) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL2234254 | 0.78 | LMNA (0.64) | LMNAMAPTENPP2MKNK1MKNK2 | |
| SCHEMBL17672944 | 0.78 | LMNA (0.64) | LMNAMAPTENPP2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132825-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS | FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) | 2025-06-26 | — | — | WO | claimed |
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-01-14 | — | — | US | claimed |
| CN-117986277-A | Parafluorobenzaldehyde derivative, preparation method thereof and application thereof in pharmacy | 南京市第一医院 | 2024-05-07 | — | — | CN | claimed |
| CN-117567509-A | Gold (I) gefitinib derivative and preparation method and application thereof | 华中科技大学同济医学院附属同济医院 | 2024-02-20 | — | — | CN | claimed |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY | 2020-06-04 | — | — | US | claimed |
| CN-111032029-A | Vascular adhesion protein-1 inhibitors for the prevention or treatment of migraine | 普罗克斯马根有限责任公司 | 2020-04-17 | — | — | CN | claimed |
| WO-2018213821-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | THE GEORGE WASHINGTON UNIVERSITY (US) | 2018-11-22 | — | — | WO | claimed |
| CN-105189494-B | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | 普罗克西梅根有限公司 | 2017-04-26 | — | — | CN | claimed |
| CN-102395567-A | Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity | EXELIXIS INC | 2012-03-28 | — | — | CN | claimed |
| CN-101074212-A | Diphenyl imidazole compound containing fluorine atom | DONGSHUO SCIENCE & TECHNOLOGY (CN) | 2007-11-21 | — | — | CN | claimed |
| CN-1655788-A | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| EP-1228069-A2 | BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS | NEUROGEN CORPORATION (US) | 2002-08-07 | — | — | EP | claimed |
| WO-2001034603-A2 | BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS | NEUROGEN CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| EP-4634178-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2025-10-14 | — | — | US | disclosed |
| WO-2025132825-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS | FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) | 2025-06-26 | — | — | WO | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0011115-A1 | Antiinflammatory 2-substituted-1H-phenanthro(9,10-d)imidazoles, their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-05-28 | — | — | EP | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194448-B2 | Catalysts for the transformation of carbon dioxide and glycerol to formic acid and lactic acid and methods of making the same | MLX, LDHA, CA2 | LMNA 416/4885MAPT 3209/4885ENPP2 1037/4885 |
| US-20200171474-A1 | CATALYSTS FOR THE TRANSFORMATION OF CARBON DIOXIDE AND GLYCEROL TO FORMIC ACID AND LACTIC ACID AND METHODS OF MAKING THE SAME | MLX, LDHA, CA2 | LMNA 416/4885MAPT 3209/4885ENPP2 1037/4885 |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | IDH2, IDH3A, IDH1 | LMNA 3684/4885MAPT 2497/4885ENPP2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.